Home>
US Stocks>
Ionis Pharmaceuticals

Ionis Pharmaceuticals share price today

(IONS)

Ionis Pharmaceuticals share price is $35.63 & ₹3,027.69 as on 21 Dec 2024, 2.30 'hrs' IST

$35.63

▲

0.04

(0.11%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Ionis Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Ionis Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Ionis Pharmaceuticals. Get details on the Indian mutual funds that are investing in Ionis Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Ionis Pharmaceuticals's financials.

Ionis Pharmaceuticals share price movements

Today's Low: $35.08
Today's High: $36.40
$35.63
1.54%
Downside
Day's Volatility :3.63%
Upside
2.12%
52 Weeks Low: $33.33
52 Weeks High: $54.44
$35.63
6.46%
Downside
52 Weeks Volatility :38.78%
Upside
34.56%

Ionis Pharmaceuticals Returns

Period	Ionis Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-14.82%	-11.1%	0.0%
6 Months	-20.26%	-6.0%	0.0%
1 Year	-30.4%	2.7%	0.0%
3 Years	10.21%	0.6%	-19.7%

Ionis Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$35.59
Open	$35.86
Today's High	$36.4
Today's Low	$35.08
Market Capitalization	$5.6B
Today's Volume	$3.8M
52 Week High	$54.4446
52 Week Low	$33.33
Revenue TTM	$803.1M
EBITDA	$-336.3M
Earnings Per Share (EPS)	$-2.44
Profit Margin	-44.68%
Quarterly Earnings Growth YOY	-0.44%
Return On Equity TTM	-73.38%

How to invest in Ionis Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Ionis Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ionis Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ionis Pharmaceuticals or IONS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ionis Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ionis Pharmaceuticals shares which would translate to 0.024 fractional shares of Ionis Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Ionis Pharmaceuticals, in just a few clicks!

Returns in Ionis Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Ionis Pharmaceuticals investment value today

Current value as on today

₹1,32,593

Returns

₹32,593

(+32.59%)

Returns from Ionis Pharmaceuticals Stock

₹30,397 (false-30.4%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Ionis Pharmaceuticals

117%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Ionis Pharmaceuticals on INDmoney from India has grown in the last 30 days as on Dec 21, 2024. 117% more investors are searching Ionis Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Ionis Pharmaceuticals

FMR Inc
14.24%
Vanguard Group Inc
9.54%
T. Rowe Price Investment Management,Inc.
8.97%
BlackRock Inc
6.54%
Wellington Management Company LLP
5.53%
Bellevue Group AG
4.99%

Analyst Recommendation on Ionis Pharmaceuticals

Buy

66%Buy

23%Hold

10%Sell

Based on 30 Wall street analysts offering stock ratings for Ionis Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 30 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Ionis Pharmaceuticals

What analysts predicted

Upside of 71.76%

Current:

$35.63

Target:

$61.20

Insights on Ionis Pharmaceuticals

Price Movement
In the last 1 month, IONS stock has moved up by 5.0%
Decreasing Revenue
Revenue is down for the last 2 quarters, 225.25M → 134.0M (in $), with an average decrease of 40.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -66.26M → -140.48M (in $), with an average decrease of 112.0% per quarter
IONS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 62.9%
IONS vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 13.8%
Price to Sales
ForIONS every $1 of sales, investors are willing to pay $6.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Ionis Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$599.7M	↑ 18.12%
Net Income	$273.7M	↓ 4685.28%
Net Profit Margin	45.65%	↑ 46.83%

	FY19	Y/Y Change
Revenue	$1.1B	↑ 87.27%
Net Income	$294.0M	↑ 7.4%
Net Profit Margin	26.18%	↓ 19.47%

	FY20	Y/Y Change
Revenue	$729.0M	↓ 35.08%
Net Income	$-487.0M	↓ 265.65%
Net Profit Margin	-66.8%	↓ 92.98%

	FY21	Y/Y Change
Revenue	$810.0M	↑ 11.11%
Net Income	$-29.0M	↓ 94.05%
Net Profit Margin	-3.58%	↑ 63.22%

	FY22	Y/Y Change
Revenue	$587.0M	↓ 27.53%
Net Income	$-270.0M	↑ 831.03%
Net Profit Margin	-46.0%	↓ 42.42%

	FY23	Y/Y Change
Revenue	$787.6M	↑ 34.18%
Net Income	$-366.3M	↑ 35.66%
Net Profit Margin	-46.5%	↓ 0.5%

	Q2 FY23	Q/Q Change
Revenue	$188.0M	↑ 43.51%
Net Income	$-85.0M	↓ 31.45%
Net Profit Margin	-45.21%	↑ 49.45%

	Q3 FY23	Q/Q Change
Revenue	$144.0M	↓ 23.4%
Net Income	$-147.0M	↑ 72.94%
Net Profit Margin	-102.08%	↓ 56.87%

	Q4 FY23	Q/Q Change
Revenue	$324.5M	↑ 125.35%
Net Income	$-9.3M	↓ 93.7%
Net Profit Margin	-2.85%	↑ 99.23%

	Q1 FY24	Q/Q Change
Revenue	$119.5M	↓ 63.18%
Net Income	$-142.8M	↑ 1441.65%
Net Profit Margin	-119.5%	↓ 116.65%

	Q2 FY24	Q/Q Change
Revenue	$225.3M	↑ 88.5%
Net Income	$-66.3M	↓ 53.6%
Net Profit Margin	-29.42%	↑ 90.08%

	Q3 FY24	Q/Q Change
Revenue	$134.0M	↓ 40.51%
Net Income	$-140.5M	↑ 112.0%
Net Profit Margin	-104.84%	↓ 75.42%

	FY18	Y/Y Change
Profit	$597.9M	↑ 349.44%

	FY19	Y/Y Change
Profit	$1.1B	↑ 87.17%

	FY20	Y/Y Change
Profit	$717.0M	↓ 35.92%

	FY21	Y/Y Change
Profit	$799.0M	↑ 11.44%

	FY22	Y/Y Change
Profit	$573.0M	↓ 28.29%

	FY23	Y/Y Change
Profit	$778.5M	↑ 35.87%

	Q2 FY23	Q/Q Change
Profit	$185.0M	↑ 42.31%

	Q3 FY23	Q/Q Change
Profit	$142.0M	↓ 23.24%

	Q4 FY23	Q/Q Change
Profit	$321.4M	↑ 126.37%

	Q1 FY24	Q/Q Change
Profit	$111.7M	↓ 65.25%

	Q2 FY24	Q/Q Change
Profit	$215.5M	↑ 92.94%

	Q3 FY24	Q/Q Change
Profit	$132.9M	↓ 38.32%

	FY18	Y/Y Change
Operating Cash Flow	$602.9M	↑ 246.19%
Investing Cash Flow	$-929.6M	↑ 159.44%
Financing Cash Flow	$475.9M	↑ 107.72%

	FY19	Y/Y Change
Operating Cash Flow	$345.7M	↓ 42.66%
Investing Cash Flow	$-41.3M	↓ 95.56%
Financing Cash Flow	$100.0M	↓ 78.98%

	FY20	Y/Y Change
Operating Cash Flow	$35.9M	↓ 89.62%
Investing Cash Flow	$274.5M	↓ 765.01%
Financing Cash Flow	$-596.6M	↓ 696.48%

	FY21	Y/Y Change
Operating Cash Flow	$30.8M	↓ 14.19%
Investing Cash Flow	$194.9M	↓ 28.99%
Financing Cash Flow	$245.9M	↓ 141.22%

	FY22	Y/Y Change
Operating Cash Flow	$-274.4M	↓ 990.84%
Investing Cash Flow	$-262.6M	↓ 234.75%
Financing Cash Flow	$-55.3M	↓ 122.48%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-97.4M	↓ 27.34%
Investing Cash Flow	$69.5M	↓ 121.35%
Financing Cash Flow	$143.5M	↓ 70.83%

Ionis Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Ionis Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ionis Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ionis Pharmaceuticals, Inc.	4.98%	-20.26%	-30.4%	10.21%	-42.63%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.11%	13.66%	87.56%
Biontech Se	4.48%	30.56%	7.36%	-56.46%	225.6%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.49%	30.99%	109.19%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-1.97%	78.33%	80.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ionis Pharmaceuticals, Inc.	524.14	NA	25.7	-2.6	-0.73	-0.07	NA	4.2
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ionis Pharmaceuticals, Inc.	Buy	$5.6B	-42.63%	524.14	-44.68%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	87.56%	17.51	33.61%
Biontech Se	Buy	$26.7B	225.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	109.19%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.59%	32.84	-4.51%

About Ionis Pharmaceuticals

ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.

Organization	Ionis Pharmaceuticals
Employees	927
CEO	Dr. Brett P. Monia Ph.D.
Industry	Health Technology

Management People of Ionis Pharmaceuticals

Name	Title
Dr. Brett P. Monia Ph.D.	Founder, CEO & Director
Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.	Executive VP of Finance & CFO
Ms. B. Lynne Parshall Esq., J.D.	Director
Dr. Richard S. Geary Ph.D.	Executive VP & Chief Development Officer
Dr. Eric E. Swayze Ph.D.	Executive Vice President of Research
Mr. Darren Gonzales	Chief Accounting Officer & Senior VP
Dr. C. Frank Bennett BSc, Ph.D.	Executive VP & Chief Scientific Officer
Mr. D. Wade Walke Ph.D.	Senior Vice President of Investor Relations
Mr. Patrick R. O'Neil Esq.	Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary
Ms. Hayley Soffer	Vice President of Corporate Communications

Important FAQs about investing in Ionis Pharmaceuticals from India :

What is Ionis Pharmaceuticals share price today?

Ionis Pharmaceuticals share price today stands at $35.63, Open: $35.86 ; Previous Close: $35.59 ; High: $36.40 ; Low: $35.08 ; 52 Week High: $54.44 ; 52 Week Low: $33.33. The stock opens at $35.86, after a previous close of $35.59. The stock reached a daily high of $36.40 and a low of $35.08, with a 52-week high of $54.44 and a 52-week low of $33.33.

Can Indians buy Ionis Pharmaceuticals shares?

Yes, Indians can invest in the Ionis Pharmaceuticals (IONS) from India.

With INDmoney, you can buy Ionis Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ionis Pharmaceuticals at zero transaction cost.

How can I buy Ionis Pharmaceuticals shares from India?

It is very easy to buy Ionis Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ionis Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Ionis Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Ionis Pharmaceuticals stocks?

To start investing in Ionis Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.